Melak Ayenalem
Department of Hematology and Immunohematology, University of Gondar, Gondar, EthiopiaPublications
-
Research Article
Dolutegravir Based Therapy Showed CD4+ T Cell Count Recovery and Viral Load Suppression among Art Naive HIV Positive Individuals: A Longitudinal Evaluation
Author(s): Teshager Gebremedhin57247, Melak Ayenalem57249, Mohammed Adem57250, Demeke Geremew57251, Yetemwork Aleka57252* and Amare Kiflie57253
Background: Recently, Dolutegravir (DTG)-based combined therapy, a more effective and safer first-line Antiretroviral Therapy (ART), has been recommended by the World Health Organization (WHO) for the treatment of Human Immunodeficiency Virus (HIV) since July 2018. However, its effectiveness in CD4+ T-cells count recovery and viral load suppression has not been studied yet in Ethiopia, where HIV is endemic. Therefore, we aimed to assess the effect of DTG-based therapy on CD4+ T-cell count and viral load count among HIV-positive patients in Ethiopia. Methods: A longitudinal prospective cohort study was conducted from July 2020-February 2021. 109 HIV-positive individuals who are ART naive but plan to initiate DTG-based therapy were recruited. HIV viral Ribonucleic Acid (RNA) copies were determined using a CD4+ .. Read More»
DOI: 10.31858/0975-8453.14.4.264-271
Abstract
How to cite this article